With this approval, durvalumab can now be used for treating patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT). Shares of Astrazeneca Pharma India Ltd ended at ₹7,479.15, up by ₹20.20, or 0.27%, on the BSE.
